Apyx Medical Corporation\'s Apyx One console gained MFDS approval December 2025 and launched commercially in South Korea Q4 2025 — bringing Renuvion technology to Korean cosmetic surgery market. The multi-functional 3-in-1 energy system (Renuvion + monopolar + bipolar) addresses wrinkles, skin laxity, and post-liposuction tissue contraction. This news article examines the technology and Korean industry implications.
What Apyx One is
- Multi-functional energy console.
- Apyx Medical Corporation manufactured.
- 3-in-1 energy system.
- Renuvion + monopolar + bipolar.
- MFDS approved December 2025.
Renuvion technology
Helium plasma technology
- Helium plasma + radiofrequency combination.
- Subdermal energy delivery.
- Tissue contraction stimulation.
- Skin tightening innovation.
Mechanism advantages
- Precise energy control.
- Less surrounding tissue damage.
- Effective skin tightening.
- Korean specialty applications.
3-in-1 system advantages
Single platform
- Multiple energy modalities.
- Flexible procedure options.
- Investment efficiency.
- Comprehensive treatment options.
Procedure flexibility
- Cutting (monopolar).
- Coagulation (bipolar).
- Tissue contraction (Renuvion).
- Single console multiple uses.
Korean cosmetic surgery applications
Wrinkle treatment
- Subdermal skin contraction.
- Mild to moderate wrinkles.
- Comprehensive aging treatment.
- Combined with other modalities.
Skin laxity
- Mild to moderate laxity.
- Subdermal tissue tightening.
- Non-surgical alternative.
- Korean specialty integration.
Post-liposuction contraction
- Body contouring enhancement.
- Skin retraction support.
- Post-weight-loss applications.
- Korean specialty technique.
Surgical adjunct
- Surgical procedure support.
- Hemostasis (bipolar).
- Cutting (monopolar).
- Comprehensive surgical platform.
Korean clinic adoption
Premium clinic interest
- Premium technology investment.
- Latest innovation access.
- Patient appeal.
- Industry maturation.
Industry positioning
- Korean cosmetic surgery innovation.
- Latest technology adoption.
- International patient draw.
- Continued leadership.
Renuvion vs other modalities
| Modality | Mechanism | Depth | Best For |
|---|---|---|---|
| Renuvion | Helium plasma + RF | Subdermal | Skin laxity, post-lipo |
| Ultherapy | HIFU | Deep SMAS | Deep tissue lifting |
| Thermage FLX | RF | Variable | Skin tightening |
| Morpheus8 | RF + microneedling | Variable | Texture + tightening |
| Sofwave | Ultrasound | Mid-dermis | Skin tightening |
Procedure details
Treatment session
- 30-90 minutes typical.
- Local or general anesthesia.
- Surgical procedure (sub-dermal).
- Outpatient procedure.
Specific applications
- Combined with liposuction often.
- Standalone skin tightening.
- Comprehensive body contouring.
- Korean specialty integration.
Recovery timeline
- 1-2 weeks initial recovery.
- Mild swelling/bruising.
- Compression garments often.
- 3-6 months final results.
- Cumulative collagen response.
Pricing in Korean clinics 2026
- Single area treatment: ₩2,000,000-₩6,000,000.
- Combined with liposuction: ₩5,000,000-₩15,000,000.
- Comprehensive body contouring: ₩10,000,000-₩25,000,000.
- USD: $1,500-$19,000 typical range.
- Premium technology pricing.
Realistic expectations
- Mild to moderate skin tightening.
- Subtle body contouring enhancement.
- Combined approach optimal.
- Long-term collagen response.
- Maintenance ongoing.
Who is a good candidate
- Mild to moderate skin laxity.
- Post-liposuction patients.
- Want non-surgical/minimally invasive.
- Realistic expectations.
- Adequate recovery time.
Who isn\'t
- Significant skin laxity (need surgery).
- Active medical conditions.
- Pacemaker considerations.
- Aggressive transformation goals.
Risks and considerations
- Surgical procedure risks.
- Bruising and swelling.
- Skin sensitivity.
- Provider experience critical.
- Need for revision possible.
Korean specialty integration
Combined with liposuction
- Korean specialty applications.
- Comprehensive body contouring.
- Refined technique integration.
- Premium service.
Multi-modal approach
- Combined with HIFU.
- Surface + deep treatment.
- Korean comprehensive approach.
- Premium clinic offerings.
For Korean patients
Domestic accessibility
- Premium Korean clinics adopting.
- Latest technology access.
- Industry investment.
- Quality service tier.
For international patients
- Korean specialty technique with Apyx One.
- Cost-effective vs home country.
- Quality reputation.
- Long-term care planning.
Industry implications
Innovation pipeline
- Korean cosmetic surgery innovation continues.
- International device adoption.
- Industry maturation.
- Long-term competitive advantage.
Apyx Medical strategy
- Korean market entry strategic.
- Asian expansion through Korea.
- Industry recognition.
- Continued international growth.
Common pitfalls
- Choosing newest technology without provider experience.
- Aggressive expectations.
- Insufficient consultation.
- Provider verification overlooked.
Best practices
- Experienced provider with Apyx One.
- Premium clinic preference.
- Comprehensive consultation.
- Realistic expectations.
- Combined approach where appropriate.
- Long-term care planning.
The honest framing
Apyx One\'s MFDS approval and Korean launch represents 2026\'s continued innovation pipeline in Korean cosmetic surgery market — Renuvion technology brings helium plasma + RF combination for skin tightening and body contouring applications. The patients who benefit most have appropriate candidacy (mild-moderate skin laxity, post-liposuction integration), choose premium clinics with experienced providers, and accept realistic expectations about non-surgical limits. The patients who pursue newest technology without provider experience or with aggressive expectations face suboptimal outcomes. Korean specialty industry continues maturation with international device adoption; the comprehensive technology platform supports refined treatment options.